Immuno-biosensor on a chip: a self-powered microfluidic-based electrochemical biosensing platform for point-of-care quantification of proteins

Abstract

Optimized self-contained microfluidic platform allows for single-step detection of proteins, through passive delivery of the dry-stored reagents required for immunosensing. Novel autonomous performance of the platform advances the point-of-care utilization of electrochemical protein sensing.

Autonomous electrochemical biosensing of glial fibrillary acidic protein for point-of-care detection of central nervous system injuries

“…As intended, this design successfully prevents the flow of the sample to the reference and counter electrodes and only maintains the sample on top of the working electrode. As opposed to our previous design, 42 this constant volume of the sample on top of the working electrode provides a more reliable concentration of the target protein being detected in the process of obtaining the calibration curve. Fig.…”

“…The microfluidic device is made of multilayer polymeric and adhesive materials that are simply laser cut and assembled in low-cost settings. As opposed to our previous self-powered microfluidic design, 42 here we confined the interaction of the biofluid sample only to the working electrode during the incubation step, eliminating any possible noise stemming from non-specific interactions and fouling of the biofluid sample with the counter and reference electrodes. The side redox preparation channel was also activated independently from the variation in the volume and physical properties of the biofluid sample which improved the reproducibility of the biosensing assay.…”

Recent advances of functional nucleic acid-based sensors for point-of-care detection of SARS-CoV-2

“…The self-powered microfluidic platform provides a good equipment base for automated virus diagnosis. The microfluidic automated electrochemical immune-sensing platform was designed for the SARS-CoV-2 N protein assay within 15 min without any liquid handling [ 22 ]. The gold-based lateral flow immunoassay (GLFIA) commonly applied in antibody/serological assays and risks exposing false-negative and false-positive interpretations is not suitable for large-scale population screening.…”

A compact, low-cost, and binary sensing (BiSense) platform for noise-free and self-validated impedimetric detection of COVID-19 infected patients

“…Multiplex electrochemical point-of-care testing (ME-POCT) devices are expected to have four major compartments: 1) reliable and reproducible electrodes created using inkjet or screen printing methods, 2) an accurate biosensing protocol for mediating the electrode surface to create accurate biosensors, 3) microfluidics for automating electrochemical biosensing steps, and 4) and an accurate and low-cost multichannel potentiostat with an easy-to-use interface for data interpretation and wireless data transfer. Despite enormous advances in developing multiplex screen printed electrodes and electrochemical biosensors ( Dhanapala et al, 2020 ; Khetani et al, 2019 ; Kinnamon et al, 2018 ; Noah and Ndangili, 2019 ; Salahandish et al 2019 , 2022a ) as well as the recent progress in self-powered microfluidic devices ( Haghayegh et al 2022a , 2022b ; Nyein et al, 2018 ; Salahandish et al, 2022b ), the realization of ME-POCT requires the development of new hand-held, rapid and remote reading, easy-to-use, noise-free, and cheaper multichannel potentiostat readers ( Alam et al, 2020 ; Bianchi et al, 2021 ).…”